Last reviewed · How we verify

NCT05118672: RESFRIN

Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment

Completed Phase 3 Last updated 22 September 2025
What this trial tests

Phase 3 trial testing Experimental drug (paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg) in Cold in 567 participants. Completed in 26 August 2025.

Timeline
26 March 2025
Primary endpoint
26 August 2025
26 August 2025

Quick facts

Lead sponsorEurofarma Laboratorios S.A.
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment567
Start date26 March 2025
Primary completion26 August 2025
Estimated completion26 August 2025
Sites2 locations across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

Eurofarma Laboratorios S.A. — full company profile →

Who can join

18 and older, any sex, with Cold or Flu Symptom. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase 3, multicenter, Randomized, Double-blind, comparative clinical trial to evaluate the association of paracetamol 500mg + Fexofenadine 60mg + Phenylephrine 20mg in the flu and common cold treatment. ⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cold

Currently open trials in the same condition.

Other Eurofarma Laboratorios S.A. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05118672.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing